Trial Profile

CITRUS Study (Comparing the Incidence Between Tiotropium and ICS/LABA in Real World Use in South Korea)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiotropium bromide (Primary) ; Corticosteroids
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms CITRUS
Sponsors Boehringer Ingelheim

Most Recent Events

19 May 2021 Results comparing the escalation time to open triple combination therapy (LAMA+LABA/ICS) from initiation of LAMA versus ICS/LABA in chronic obstructive lung disease management, presented at the 117th International Conference of the American Thoracic Society.
15 Jan 2021 Status changed from active, no longer recruiting to completed.
09 Dec 2020 Planned End Date changed from 30 Nov 2020 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com